Clinical Trial News and Research

RSS

Gene therapy protects eye cells in mice with retinitis pigmentosa

A gene therapy protects eye cells in mice with a rare disorder that causes vision loss, especially when used in combination with other gene therapies, shows a study published today in eLife.

15 Apr 2021

Researchers identify and test drug combination that exploits a weakness in small cell lung cancer

Researchers from the National Institutes of Health have identified and tested a drug combination that exploits a weakness in small cell lung cancer (SCLC), an aggressive, dangerous cancer.

13 Apr 2021

New method can improve the drug testing process

When developing a new drug, the first question is, “does it work?” and the second question is, “is it harmful?”

9 Apr 2021

New stem cell therapy shows promise to help patients with non-healing diabetic foot ulcers

According to the results of a phase 1 clinical trial just published in STEM CELLS Translational Medicine, a new stem cell therapy shows promise of making diabetes-related amputations a thing of the past.

8 Apr 2021

Scientists discover mutations that make cancer resistant to KRAS-targeted therapies

A gene called KRAS is one of the most commonly mutated genes in all human cancers, and targeted drugs that inhibit the protein expressed by mutated KRAS have shown promising results in clinical trials, with potential approvals by the U.S. Food and Drug Administration anticipated later this year.

7 Apr 2021

Low K777 concentrations inhibit cathepsin L and reduce SARS-CoV-2’s ability to infect host cell lines

For a long time, James McKerrow, MD, PhD, dean of the Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California San Diego, has investigated neglected tropical diseases, which are chronic, disabling parasitic infections mainly affecting the poor and underserved communities in developing nations.

From UC San Diego 5 Apr 2021

Researchers use mathematical modeling to explain CAR T-cell therapy dynamics

Chimeric antigen receptor T-cell therapy, or CAR T, is a relatively new type of therapy approved to treat several types of aggressive B cell leukemias and lymphomas.

26 Mar 2021

Genetically engineered immune cells deliver anticancer signal to organs to prevent metastasis

Scientists have genetically engineered immune cells, called myeloid cells, to precisely deliver an anticancer signal to organs where cancer may spread.

From National Cancer Institute (NCI) 25 Mar 2021

Nutritional supplement may reduce the risk of strokes caused by a rare genetic disorder

Researchers from Children's Hospital of Philadelphia (CHOP) have discovered that a widely used nutritional supplement may significantly reduce the risk of fatal strokes caused by a rare genetic disorder.

24 Mar 2021

Hormone drugs may help disarm coronavirus spike protein and stop disease progression

Hormone drugs that reduce androgen levels may help disarm the coronavirus spike protein used to infect cells and stop the progression of severe COVID-19 disease, suggests a new preclinical study from researchers in the Abramson Cancer Center at the University of Pennsylvania and published online in Cell Press's iScience.

23 Mar 2021

Study reveals substantial difference in selection and timing of genetic tests for non-small-cell lung cancer

During biomarker testing, certain disease-associated molecules are examined to estimate the progression of a disease and its response to treatments.

17 Mar 2021

Engineered safety switch reduces CAR-T immunotherapy-related side effects

UNC Lineberger Comprehensive Cancer Center researchers have successfully used an experimental safety switch, incorporated as part of a chimeric antigen receptor T-cell (CAR-T) therapy, a type of immunotherapy, to reduce the severity of treatment side effects that sometimes occur.

5 Mar 2021

Epigenetic therapy can boost the ability of immune killer T-cells to destroy cancer cells

Developing “super soldiers” of particular white blood cells to promote an anti-tumor reaction has been demonstrated in a series of well-designed experiments.

23 Feb 2021

First-in-human clinical trial to test safety, efficacy of gene therapy for Alzheimer's disease

Researchers at University of California San Diego School of Medicine have launched a first-in-human Phase I clinical trial to assess the safety and efficacy of a gene therapy to deliver a key protein into the brains of persons with Alzheimer's disease (AD) or Mild Cognitive Impairment (MCI), a condition that often precedes full-blown dementia.

From UC San Diego 19 Feb 2021

Gut microbiome alterations help melanoma patients to respond to immunotherapy

Statistical modeling developed by Oregon State University researchers has confirmed that changes to melanoma patients' gut microbiome led them to respond to a type of treatment capable of providing long-term benefit.

17 Feb 2021

Gene-based blood test may predict treatment success in people with metastatic melanoma

A test that monitors blood levels of DNA fragments released by dying tumor cells may serve as an accurate early indicator of treatment success in people in late stages of one of the most aggressive forms of skin cancer, a new study finds.

From New York University (NYU) 15 Feb 2021

Genomic test helps identify prostate cancer patients who may benefit from hormone therapy

A commercially available genomic test may help oncologists better determine which patients with recurrent prostate cancer may benefit from hormone therapy, according to new research from the Johns Hopkins Kimmel Cancer Center and 15 other medical centers.

12 Feb 2021

Scientists use new approach to avert drug resistance in glioblastomas

In far too many cases over the years, scientists have discovered promising new cancer treatments, only to report later that the tumor cells found ways to become resistant. These disappointing results have made overcoming drug resistance a major goal in cancer research.

11 Feb 2021

Fecal microbiota transplant helps cancer patients respond to immunotherapy

For patients with cancers that do not respond to immunotherapy drugs, adjusting the composition of microorganisms in the intestines--known as the gut microbiome--through the use of a stool, or fecal, transplants may help some of these individuals respond to the immunotherapy drugs, a new study suggests.

From National Cancer Institute (NCI) 5 Feb 2021

Investigational antisense medicine lowers disease burden, reduces myeloma cell abundance in mice

Many patients with multiple myeloma, a type of blood cancer, eventually develop resistance to one treatment after another. That's in part because cancer stem cells drive the disease -- cells that continually self-renew. If a therapy can't completely destroy these malignant stem cells, the cancer is likely to keep coming back.

From UC San Diego 21 Jan 2021